Aliases & Classifications for Liposarcoma

MalaCards integrated aliases for Liposarcoma:

Name: Liposarcoma 12 77 54 56 45 15 17 74

Classifications:



Summaries for Liposarcoma

NIH Rare Diseases : 54 Liposarcoma is a tumor that arises from fat tissue. This tumor often occurs in the thigh, legs, behind the knee, or in the abdomen, but it can be found in other parts of the body, in the retroperitoneum; and, less often, in the head and neck area. Their primary occurrence in the skin is rare. Because a liposarcoma may grow into surrounding tissues or organs, it is considered a malignant tumor. The World Health Organization classification of soft tissue tumors recognizes 5 types of liposarcomas: Well differentiated, which includes the adipocytic, sclerosing, and inflammatory subtypes; dedifferentiated; myxoid; round cell; and pleomorphic. Most patients with liposarcoma have no symptoms until the tumor is large and invades the neighboring organs or tissues, causing tenderness, pain, or functional problems. Although surgical removal of the tumor is the curative treatment, some patients may benefit from chemotherapy and radiation. Most patients with liposarcoma have no symptoms until the tumor is large and impinges on neighboring structures, causing tenderness, pain, or functional disturbances. In the retroperitoneal area, where liposarcoma is detected at a late stage, the tumor may grow to a substantial size, weighing several pounds at the time of diagnosis. In general, liposarcoma grows silently, and the patient's estimation of the clinical duration is often unreliable. The patient eventually becomes aware of a swelling or a mass and reports this finding to the physician. Patients may report the following: Associated episode of trauma to the region containing the mass Painful swelling (occurs in one third of cases for as long as 6 mo) Decreased function (ie, range of motion) Numbness Enlargement of varicose veins Fatigue Abdominal pain Weight loss Nausea Vomiting 

MalaCards based summary : Liposarcoma is related to cellular myxoid liposarcoma and myxoid liposarcoma. An important gene associated with Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Ifosfamide and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and t cells, and related phenotypes are subcutaneous nodule and sarcoma

Disease Ontology : 12 A lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities.

Wikipedia : 77 Liposarcoma is a cancer that arises in fat cells in soft tissue, such as that inside the thigh or in the... more...

Related Diseases for Liposarcoma

Diseases in the Liposarcoma family:

Adult Liposarcoma Inflammatory Liposarcoma

Diseases related to Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 324)
# Related Disease Score Top Affiliating Genes
1 cellular myxoid liposarcoma 33.7 CDK4 EWSR1 FUS MDM2
2 myxoid liposarcoma 33.6 CDK4 DDIT3 EWSR1 FUS HMGA2 LRP1
3 pleomorphic liposarcoma 33.6 CDKN2A DES MDM2 VIM
4 dedifferentiated liposarcoma 33.3 CDK4 CDKN2A DES HMGA2 MDM2 TP53
5 well-differentiated liposarcoma 33.0 CDK4 CDKN2A FRS2 HMGA2 MDM2 TSPAN31
6 sclerosing liposarcoma 32.9 CD34 FUS MB MDM2 TP53
7 spindle cell liposarcoma 32.9 CALB2 CD34 CDK4 DDIT3 MDM2
8 mixed liposarcoma 32.9 CD34 CDK4 DDIT3 FUS MB MDM2
9 atypical lipomatous tumor 32.2 CDK4 CDKN2A FUS HMGA2 MDM2 TSPAN31
10 pleomorphic lipoma 31.4 HMGA2 MDM2
11 lipomatosis, multiple 30.9 CDK4 DES FUS HMGA2 MDM2
12 myxofibrosarcoma 30.8 DES FUS MDM2
13 malignant fibroxanthoma 30.7 CDK4 DES MDM2 VIM
14 fibrous histiocytoma 30.6 DES EWSR1 FUS VIM
15 sarcoma 30.4 CDK4 DDIT3 EWSR1 FUS MDM2 TP53
16 spindle cell sarcoma 30.4 DES MDM2 VIM
17 hemangiopericytoma, malignant 30.3 DES MDM2 VIM
18 angiolipoma 30.3 DES VIM
19 li-fraumeni syndrome 30.3 CDKN2A MDM2 TP53
20 mesenchymoma 30.3 DES HMGA2 MB MDM2
21 soft tissue sarcoma 30.3 EWSR1 MDM2 TP53
22 sarcomatosis 30.1 EWSR1 HMGA2
23 spindle cell lipoma 30.1 CDK4 DES MDM2 VIM
24 leiomyosarcoma 30.1 CDK4 DES MB MDM2 TP53 VIM
25 carcinosarcoma 30.0 DES TP53 VIM
26 infiltrating lipoma 30.0 CD34 CDK4 HMGA2 MDM2
27 retinoblastoma 30.0 CDK4 CDKN2A MDM2 TP53
28 histiocytoma 30.0 EWSR1 FUS MB MDM2 TP53 TSPAN31
29 retroperitoneal fibrosis 30.0 MDM2 VIM
30 chondroid lipoma 30.0 CDK4 DDIT3 FUS MDM2
31 malignant peripheral nerve sheath tumor 29.9 CDK4 CDKN2A MDM2 TP53 VIM
32 malignant mesenchymoma 29.8 CDK4 DES EWSR1 MB MDM2 TP53
33 leiomyoma 29.8 CD34 DES HMGA2 VIM
34 chordoma 29.8 CDKN2A DES VIM
35 pleomorphic adenoma 29.8 HMGA2 MDM2 TP53 VIM
36 inflammatory myofibroblastic tumor 29.8 CDK4 DES MDM2 TP53 VIM
37 rhabdomyosarcoma 29.6 CDK4 DES EWSR1 MB MDM2 TP53
38 sarcoma, synovial 29.5 CALB2 DES HMGA2 MDM2 VIM
39 gastrointestinal stromal tumor 29.4 CD34 CDKN2A DES TP53 VIM
40 larynx liposarcoma 12.4
41 kidney liposarcoma 12.4
42 myxoid liposarcoma of the ovary 12.4
43 mediastinum liposarcoma 12.4
44 retroperitoneal liposarcoma 12.3
45 gastric liposarcoma 12.2
46 breast liposarcoma 12.2
47 inflammatory liposarcoma 12.2
48 esophagus liposarcoma 12.2
49 liposarcoma of the ovary 12.2
50 cutaneous liposarcoma 12.2

Graphical network of the top 20 diseases related to Liposarcoma:



Diseases related to Liposarcoma

Symptoms & Phenotypes for Liposarcoma

Human phenotypes related to Liposarcoma:

33 (show all 9)
# Description HPO Frequency HPO Source Accession
1 subcutaneous nodule 33 hallmark (90%) HP:0001482
2 sarcoma 33 hallmark (90%) HP:0100242
3 nausea and vomiting 33 occasional (7.5%) HP:0002017
4 fatigue 33 occasional (7.5%) HP:0012378
5 abdominal pain 33 occasional (7.5%) HP:0002027
6 weight loss 33 occasional (7.5%) HP:0001824
7 paresthesia 33 occasional (7.5%) HP:0003401
8 abnormality of the kidney 33 occasional (7.5%) HP:0000077
9 varicose veins 33 occasional (7.5%) HP:0002619

GenomeRNAi Phenotypes related to Liposarcoma according to GeneCards Suite gene sharing:

27 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.13 VIM
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.13 FUS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.13 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.13 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.13 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.13 VIM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.13 FUS
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.13 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.13 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.13 VIM
11 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.13 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.13 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.13 FUS PPARG TP53 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.13 FUS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.13 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.13 FUS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.13 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.13 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.13 PPARG
20 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.13 FUS TP53
21 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.13 FUS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.13 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.13 FUS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.13 FUS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.13 FUS
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.13 VIM
27 Reduced mammosphere formation GR00396-S 9.23 CD34 CDK4 DDIT3 DES FRS2 MDM2

MGI Mouse Phenotypes related to Liposarcoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 CD34 CDK4 CDKN2A DDIT3 DES FRS2
2 cardiovascular system MP:0005385 10.26 CDK4 CDKN2A DDIT3 DES FRS2 LRP1
3 behavior/neurological MP:0005386 10.24 CALB2 CDK4 CDKN2A DDIT3 DES LRP1
4 hematopoietic system MP:0005397 10.18 CD34 CDK4 CDKN2A DDIT3 LRP1 MB
5 homeostasis/metabolism MP:0005376 10.18 CD34 CDK4 CDKN2A DDIT3 DES LRP1
6 embryo MP:0005380 10.13 CDK4 CDKN2A FRS2 LRP1 MB MDM2
7 integument MP:0010771 9.92 CD34 CDK4 CDKN2A LRP1 MDM2 PPARG
8 liver/biliary system MP:0005370 9.86 CDK4 CDKN2A DDIT3 LRP1 MDM2 PPARG
9 muscle MP:0005369 9.81 CDK4 CDKN2A DES LRP1 MB MDM2
10 neoplasm MP:0002006 9.5 CD34 CDK4 CDKN2A DDIT3 MDM2 PPARG
11 nervous system MP:0003631 9.36 CALB2 CDK4 CDKN2A DDIT3 FRS2 LRP1

Drugs & Therapeutics for Liposarcoma

Drugs for Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
2
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Trabectedin Approved, Investigational Phase 3,Phase 1,Phase 2 114899-77-3 108150
5
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
6
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
9
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
10
Carboplatin Approved Phase 3,Phase 2 41575-94-4 38904 10339178 498142
11
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
12
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
15 Olaratumab Approved, Investigational Phase 3,Phase 2 1024603-93-7
16
Cyproheptadine Approved Phase 3 129-03-3 2913
17
Histamine Approved, Investigational Phase 3 51-45-6 774
18
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
19
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
21 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
23 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
25 Immunologic Factors Phase 3,Phase 1,Phase 2
26 Pharmaceutical Solutions Phase 3,Phase 2
27 Etoposide phosphate Phase 3,Phase 2
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
31 Antirheumatic Agents Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
34 Antimetabolites Phase 3,Phase 2,Phase 1
35 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Gastrointestinal Agents Phase 3,Phase 2
38 Neurotransmitter Agents Phase 3,Phase 1
39 Serotonin Agents Phase 3
40 Serotonin Antagonists Phase 3
41 Histamine H1 Antagonists Phase 3
42 Anti-Allergic Agents Phase 3
43
Histamine Phosphate Phase 3 51-74-1 65513
44 Histamine Antagonists Phase 3
45 Antipruritics Phase 3
46 Dermatologic Agents Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
49
Palbociclib Approved, Investigational Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3

Interventional clinical trials:

(show top 50) (show all 131)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
4 A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
5 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Completed NCT00423618 Phase 3
11 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
12 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
13 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
14 Selinexor in Advanced Liposarcoma Recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
15 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
16 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
17 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
18 Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin Not yet recruiting NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 Brostallicin Clinical Trial for Myxoid Liposarcoma Unknown status NCT00633165 Phase 2 Brostallicin
21 A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma Unknown status NCT02571829 Phase 2 ribociclib
22 Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
23 Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Unknown status NCT02275286 Phase 1, Phase 2 Trabectedin
24 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
25 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
26 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
27 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed NCT01506596 Phase 2 pazopanib
28 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Completed NCT01692496 Phase 2 Pazopanib
29 PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed NCT01209598 Phase 2 Palbociclib 200mg;Palbociclib 125mg
30 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
31 Rosiglitazone in Treating Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
32 Troglitazone in Treating Patients With Liposarcoma Completed NCT00003058 Phase 2 troglitazone
33 A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
34 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
35 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
36 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
37 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
38 Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Completed NCT00093080 Phase 2 ridaforolimus
39 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
40 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
41 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
42 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
43 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
44 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
45 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
46 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
47 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
48 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
49 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
50 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate

Search NIH Clinical Center for Liposarcoma

Cochrane evidence based reviews: liposarcoma

Genetic Tests for Liposarcoma

Anatomical Context for Liposarcoma

MalaCards organs/tissues related to Liposarcoma:

42
Bone, Breast, T Cells, Adipocyte, Skin, Kidney, Liver

Publications for Liposarcoma

Articles related to Liposarcoma:

(show top 50) (show all 2408)
# Title Authors Year
1
Orbital Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma Masquerading as Pleomorphic Lipoma: A Diagnostic Challenge. ( 30908464 )
2019
2
Two-stage surgery for intraperitoneal and retroperitoneal multicentric liposarcoma causing hydronephrosis: a case report. ( 30715629 )
2019
3
Retroperitoneal Liposarcoma: A Concern in Inguinal Hernia Repair. ( 30700965 )
2019
4
Primary anatomical site, adjuvant therapy, and other prognostic variables for dedifferentiated liposarcoma. ( 30361927 )
2019
5
Rapidly growing pleural liposarcoma masquerading as extrapleural hematoma. ( 30511801 )
2019
6
An Unusual Case of Cecal Mesenteric Dedifferentiated Liposarcoma Involving the Ileocolic Artery Resected by Right Hemicolectomy. ( 30591499 )
2019
7
Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. ( 30602058 )
2019
8
Optimal maximum duration for delaying salvage operation when recurrence of retroperitoneal liposarcoma is suspected: a single-center study. ( 30604162 )
2019
9
68Ga-Prostate-Specific Membrane Antigen PET/CT: Incidental Finding of a Liposarcoma. ( 30608915 )
2019
10
Scrotal abscess mimicking as intrascrotal liposarcoma. ( 30619715 )
2019
11
Recurrent oesophageal intraluminal liposarcoma in a woman. ( 30649254 )
2019
12
JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma. ( 30650179 )
2019
13
AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK. ( 30654529 )
2019
14
Pleural dedifferentiated liposarcoma: A case report. ( 30655988 )
2019
15
Malignant Interventricular Liposarcoma. ( 30682419 )
2019
16
A giant retroperitoneal liposarcoma with renal involvement: A case report and literature review. ( 30772091 )
2019
17
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. ( 30787173 )
2019
18
Identification of CCDC180 and LRRC4 as Potential Immunohistochemical Markers for Liposarcoma Based on Proteomic Analysis Using Formalin-Fixed, Paraffin-Embedded Tissue. ( 30790560 )
2019
19
Spindle cell liposarcoma with a TRIO-TERT fusion transcript. ( 30793229 )
2019
20
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma. ( 30795553 )
2019
21
Pleomorphic liposarcoma of chest wall: a rare entity with challenging management. ( 30808192 )
2019
22
miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGFβ, and Wnt signaling. ( 30824765 )
2019
23
Recurrent intrathoracic dedifferentiated liposarcoma: A case report and literature review. ( 30847274 )
2019
24
Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review. ( 30852045 )
2019
25
Pleomorphic liposarcoma: Updates and current differential diagnosis. ( 30852046 )
2019
26
Kidney sparing giant retroperitoneal liposarcoma: Case report and literature review. ( 30856580 )
2019
27
Primary parotid liposarcoma. ( 30876853 )
2019
28
Pancreatic liposarcoma: A rare cause of pancreatic mass in adult. ( 30883897 )
2019
29
Requirement for YAP1 signaling in myxoid liposarcoma. ( 30898787 )
2019
30
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma. ( 30903020 )
2019
31
Short tau inversion recovery magnetic resonance imaging for staging and screening in myxoid liposarcoma. ( 30906124 )
2019
32
Dedifferentiated liposarcoma of the musculoskeletal system: expanded MR imaging spectrum from predominant fatty mass to non-fatty mass. ( 30907094 )
2019
33
Dedifferentiated Liposarcoma Occurring in the Right Pulmonary Hilum. ( 29491279 )
2018
34
Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. ( 29932244 )
2018
35
Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation Producing HCG: A Case Report of a Diagnostic Pitfall. ( 29532681 )
2018
36
Arginine methylation of translocated in liposarcoma (TLS) inhibits its binding to long noncoding RNA, abrogating TLS-mediated repression of CBP/p300 activity. ( 29784880 )
2018
37
Amplification of FRS2 in atypical lipomatous tumour/well -differentiated liposarcoma and dedifferentiated liposarcoma: a clinicopathological and genetic study of 146 cases. ( 29368794 )
2018
38
Corrigendum to "Pericytic mimicry in well-differentiated liposarcoma/atypical lipomatous tumor" (Hum Pathol 2016;54:92-99). ( 29958690 )
2018
39
Primary endobronchial liposarcoma successfully resected via bronchoscopy: A rare case report with genetic analysis. ( 29963153 )
2018
40
Dedifferentiated liposarcoma of the oral floor: A case study and literature review of 50 cases of head and neck neoplasm. ( 29740489 )
2018
41
A retrospective, single-center cohort study on 65 patients with primary retroperitoneal liposarcoma. ( 29434876 )
2018
42
A rare case of primary small bowel de-differentiated liposarcoma causing intussusception: A case report. ( 29901613 )
2018
43
Whole blood miRNA expression analysis reveals miR-3613-3p as a potential biomarker for dedifferentiated liposarcoma. ( 29689704 )
2018
44
Giant Primary Retroperitoneal Dedifferentiated Liposarcoma. ( 29959642 )
2018
45
Pleomorphic liposarcoma: An analysis of 6 case reports and literature review. ( 29465602 )
2018
46
Well-Differentiated Liposarcoma (Atypical Lipomatous Tumor) Presenting as an Esophageal Polyp. ( 29349606 )
2018
47
Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients. ( 29558901 )
2018
48
Pleomorphic liposarcoma of bone: a rare primary malignant bone tumour. ( 29449935 )
2018
49
Extensive renal sinus lipomatosis in xanthogranulomatous pyelonephritis simulating liposarcoma. ( 29522292 )
2018
50
Simultaneous pulmonary and inferior vena cava tumor thromboembolism secondary to retroperitoneal pleomorphic liposarcoma. ( 29550849 )
2018

Variations for Liposarcoma

Cosmic variations for Liposarcoma:

9 (show top 50) (show all 236)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6933566 ZFHX3 soft tissue,fat,liposarcoma,NS c.7624T>C p.F2542L 16:72795058-72795058 0
2 COSM6978413 ZFHX3 soft tissue,fat,liposarcoma,myxoid-round cell c.448C>A p.L150M 16:72959698-72959698 0
3 COSM6922065 YES1 soft tissue,fat,liposarcoma,NS c.166A>G p.S56G 18:756662-756662 0
4 COSM3054546 XPO1 soft tissue,fat,liposarcoma,myxoid-round cell c.1288G>T p.V430L 2:61493011-61493011 0
5 COSM6987297 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.223G>A p.E75K 11:32434919-32434919 0
6 COSM6986268 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 0
7 COSM11333 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 17:7675113-7675113 0
8 COSM10646 TP53 soft tissue,fat,liposarcoma,NS c.725G>A p.C242Y 17:7674238-7674238 0
9 COSM44723 TP53 soft tissue,fat,liposarcoma,NS c.674T>C p.V225A 17:7674289-7674289 0
10 COSM44094 TP53 soft tissue,fat,liposarcoma,NS c.716A>G p.N239S 17:7674247-7674247 0
11 COSM10659 TP53 soft tissue,fat,liposarcoma,NS c.817C>T p.R273C 17:7673803-7673803 0
12 COSM10648 TP53 soft tissue,fat,liposarcoma,NS c.524G>A p.R175H 17:7675088-7675088 0
13 COSM10672 TP53 soft tissue,fat,liposarcoma,NS c.577C>T p.H193Y 17:7674954-7674954 0
14 COSM43663 TP53 soft tissue,fat,liposarcoma,NS c.826G>C p.A276P 17:7673794-7673794 0
15 COSM10941 TP53 soft tissue,fat,liposarcoma,NS c.730G>A p.G244S 17:7674233-7674233 0
16 COSM10647 TP53 soft tissue,fat,liposarcoma,NS c.404G>T p.C135F 17:7675208-7675208 0
17 COSM44512 TP53 soft tissue,fat,liposarcoma,NS c.740A>G p.N247S 17:7674223-7674223 0
18 COSM10656 TP53 soft tissue,fat,liposarcoma,NS c.742C>T p.R248W 17:7674221-7674221 0
19 COSM43687 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 0
20 COSM45794 TP53 soft tissue,fat,liposarcoma,NS c.421T>G p.C141G 17:7675191-7675191 0
21 COSM11059 TP53 soft tissue,fat,liposarcoma,NS c.713G>A p.C238Y 17:7674250-7674250 0
22 COSM44112 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 17:7674891-7674891 0
23 COSM10654 TP53 soft tissue,fat,liposarcoma,NS c.637C>T p.R213* 17:7674894-7674894 0
24 COSM11245 TP53 soft tissue,fat,liposarcoma,NS c.430C>T p.Q144* 17:7675182-7675182 0
25 COSM43632 TP53 soft tissue,fat,liposarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 0
26 COSM10731 TP53 soft tissue,fat,liposarcoma,NS c.707A>G p.Y236C 17:7674256-7674256 0
27 COSM6901 TP53 soft tissue,fat,liposarcoma,NS c.559+1G>A p.? 17:7675052-7675052 0
28 COSM4465309 TNFAIP3 soft tissue,fat,liposarcoma,NS c.1376C>T p.S459L 6:137878821-137878821 0
29 COSM6848516 TET2 soft tissue,fat,liposarcoma,myxoid-round cell c.3809C>T p.T1270I 4:105259624-105259624 0
30 COSM6924539 SMARCA4 soft tissue,fat,liposarcoma,NS c.3940G>T p.D1314Y 19:11034189-11034189 0
31 COSM4774989 SH2B3 soft tissue,upper leg,sarcoma,NS c.232G>A p.E78K 12:111418377-111418377 0
32 COSM7002390 SETD2 soft tissue,fat,liposarcoma,NS c.4604C>T p.T1535I 3:47062343-47062343 0
33 COSM6921522 SDHA soft tissue,fat,liposarcoma,myxoid-round cell c.664T>G p.L222V 5:228227-228227 0
34 COSM6942711 ROS1 soft tissue,fat,liposarcoma,NS c.1453T>C p.S485P 6:117389656-117389656 0
35 COSM1437480 RICTOR soft tissue,fat,liposarcoma,NS c.3404C>T p.T1135M 5:38950444-38950444 0
36 COSM6967634 RBM10 soft tissue,fat,liposarcoma,NS c.443A>G p.Q148R 23:47173138-47173138 0
37 COSM1651764 RB1 soft tissue,fat,liposarcoma,NS c.1818T>A p.Y606* 13:48456207-48456207 0
38 COSM6966300 RB1 soft tissue,fat,liposarcoma,NS c.2632G>A p.D878N 13:48476812-48476812 0
39 COSM6906362 RAF1 soft tissue,fat,liposarcoma,NS c.1141G>A p.D381N 3:12591760-12591760 0
40 COSM5106 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.335T>C p.L112P 10:87933094-87933094 0
41 COSM5135 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.106G>A p.G36R 10:87894051-87894051 0
42 COSM5039 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.518G>A p.R173H 10:87952143-87952143 0
43 COSM1167954 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.485A>T p.D162V 10:87933244-87933244 0
44 COSM5198 PTEN soft tissue,fat,liposarcoma,NS c.72C>G p.D24E 10:87864541-87864541 0
45 COSM3416650 POLE soft tissue,fat,liposarcoma,myxoid-round cell c.2275C>T p.R759C 12:132667547-132667547 0
46 COSM6987724 PLK2 soft tissue,fat,liposarcoma,myxoid-round cell c.1337G>C p.R446P 5:58456073-58456073 0
47 COSM6967036 PLCG2 soft tissue,fat,liposarcoma,NS c.3232C>T p.R1078* 16:81938834-81938834 0
48 COSM2155617 PIK3R1 soft tissue,fat,liposarcoma,NS c.1135A>G p.K379E 5:68293319-68293319 0
49 COSM763 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1633G>A p.E545K 3:179218303-179218303 0
50 COSM775 PIK3CA soft tissue,fat,liposarcoma,NS c.3140A>G p.H1047R 3:179234297-179234297 0

Copy number variations for Liposarcoma from CNVD:

7 (show all 36)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13334 1 1 124300000 Gain Liposarcoma
2 16445 1 124300000 247249719 Loss Liposarcoma
3 20078 1 15300000 163800000 Amplification COAS1 Liposarcoma
4 20079 1 15300000 163800000 Amplification COAS2 Liposarcoma
5 20080 1 15300000 163800000 Amplification COAS3 Liposarcoma
6 20084 1 15300000 212100000 Gain Liposarcoma
7 42815 10 40300000 135374737 Loss Liposarcoma
8 55437 11 52900000 134452384 Loss Liposarcoma
9 61489 12 1 14800000 Loss Liposarcoma
10 67172 12 37282278 37312244 Amplified CHOP Liposarcoma
11 67787 12 44600000 69800000 Gain CDK4 liposarcomas
12 67788 12 44600000 69800000 Gain HMGA2 liposarcomas
13 67789 12 44600000 69800000 Gain MDM2 liposarcomas
14 69651 12 56140200 56152312 Amplified GLI1 Liposarcoma
15 69861 12 56374152 56401607 Amplified OS9 Liposarcoma
16 69873 12 56425050 56428293 Amplified TSPAN31 Liposarcoma
17 69880 12 56428269 56432431 Amplified CDK4 Liposarcoma
18 70737 12 64503703 64646338 Amplified HMGA2 Liposarcoma
19 71088 12 67488246 67520481 Amplified MDM2 Liposarcoma
20 77049 13 39500000 52200000 Loss Liposarcoma
21 77649 13 46200000 52200000 Deletion RB1 Liposarcoma
22 78496 13 52200000 114142980 Loss Liposarcoma
23 106733 17 1 11200000 Deletion Liposarcoma
24 108852 17 23200000 28800000 Deletion Liposarcoma
25 139560 2 183406981 183439743 Amplified OS1 Liposarcoma
26 149783 2 93300000 242951149 Gain Liposarcoma
27 149786 2 93300000 242951149 Loss Liposarcoma
28 166153 3 1 91700000 Gain Liposarcoma
29 166161 3 1 91700000 Loss Liposarcoma
30 179460 3 91700000 199501827 Gain Liposarcoma
31 187537 4 50700000 191273063 Loss Liposarcoma
32 191663 5 1 45800000 Gain Liposarcoma
33 200009 5 47700000 180857866 Gain Liposarcoma
34 210239 6 29900000 45200000 Gain Liposarcoma
35 217105 7 1 59100000 Gain Liposarcoma
36 225569 7 47600000 107200000 Gain Liposarcoma

Expression for Liposarcoma

Search GEO for disease gene expression data for Liposarcoma.

Pathways for Liposarcoma

Pathways related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 CDK4 CDKN2A MDM2 PPARG TP53
2 12.71 CDK4 CDKN2A MDM2 PPARG TP53
3 12.31 CDKN2A HMGA2 MDM2 TP53 VIM
4 12.27 CDK4 CDKN2A MDM2 TP53 VIM
5
Show member pathways
12.25 CDK4 CDKN2A MDM2 TP53
6 12.23 CDK4 CDKN2A GPS2 TP53
7 12.23 CDK4 CDKN2A MDM2 TP53
8 12.14 CDK4 CDKN2A MDM2 TP53
9 12.11 DDIT3 EWSR1 FUS YBX1
10 12 CDK4 CDKN2A MDM2 TP53
11 11.72 CDK4 MDM2 TP53
12 11.71 CDK4 CDKN2A MDM2 TP53
13 11.6 CDKN2A MDM2 TP53
14
Show member pathways
11.59 CDKN2A MDM2 TP53
15 11.44 DDIT3 EWSR1 FUS HMGA2 MDM2 PPARG
16 11.42 CDKN2A MDM2 TP53
17 11.32 CDK4 MDM2 TP53
18 11.32 CDK4 CDKN2A MDM2 TP53
19 11.28 CDK4 MDM2 TP53
20 10.84 CDKN2A MDM2 TP53
21
Show member pathways
10.78 CDKN2A MDM2 TP53
22 10.76 CDK4 CDKN2A MDM2 TP53

GO Terms for Liposarcoma

Cellular components related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 CALB2 CDK4 CDKN2A DDIT3 DES EWSR1
2 cytoplasm GO:0005737 9.55 CALB2 CD34 CDK4 CDKN2A DDIT3 DES
3 senescence-associated heterochromatin focus GO:0035985 9.26 CDKN2A HMGA2
4 nucleoplasm GO:0005654 10.02 CDK4 CDKN2A DDIT3 FUS GPS2 HMGA2
5 cytosol GO:0005829 10 CALB2 CDK4 CDKN2A DDIT3 DES FRS2

Biological processes related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.95 DDIT3 GPS2 HMGA2 MDM2 PPARG TP53
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 CDKN2A DDIT3 GPS2 HMGA2 PPARG TP53
3 negative regulation of transcription, DNA-templated GO:0045892 9.73 CDKN2A DDIT3 HMGA2 MDM2 PPARG TP53
4 positive regulation of apoptotic process GO:0043065 9.72 CDK4 CDKN2A HMGA2 PPARG TP53
5 negative regulation of neuron projection development GO:0010977 9.58 LRP1 MDM2 VIM
6 positive regulation of cholesterol efflux GO:0010875 9.55 GPS2 LRP1
7 replicative senescence GO:0090399 9.54 CDKN2A TP53
8 ER overload response GO:0006983 9.52 DDIT3 TP53
9 negative regulation of telomerase activity GO:0051974 9.51 PPARG TP53
10 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.49 DDIT3 TP53
11 amyloid fibril formation GO:1990000 9.46 CDKN2A MDM2
12 lens fiber cell development GO:0070307 9.43 FRS2 VIM
13 cellular response to actinomycin D GO:0072717 9.16 MDM2 TP53
14 positive regulation of gene expression GO:0010628 9.1 CD34 CDKN2A HMGA2 MDM2 TP53 VIM
15 senescence-associated heterochromatin focus assembly GO:0035986 8.96 CDKN2A HMGA2

Molecular functions related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.56 DDIT3 HMGA2 PPARG TP53
2 identical protein binding GO:0042802 9.56 DES EWSR1 FUS MDM2 PPARG TP53
3 disordered domain specific binding GO:0097718 9.33 CDKN2A MDM2 TP53
4 transcription factor binding GO:0008134 9.1 CD34 CDKN2A DDIT3 HMGA2 PPARG TP53

Sources for Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....